itraconazol
Safety margins
Weight | ROA | Dosage |
---|---|---|
ROA: po |
Dosage: min. 100mg 1 dd to max. 200mg 2 dd |
|
ROA: iv |
Dosage: min. 100mg 1 dd to max. 200mg 2 dd |
Kidney function
ROA | GFR | Dosage | Interval | Comments |
---|---|---|---|---|
ROA: iv | ||||
GFR: <30 |
Dosage: do not prescribe |
Comments: oraal mag wel |
Renal function-replacement therapy
CAPD: Aanpassen van de dosis of het doseerinterval is niet nodig. Itraconazol is slecht oplosbaar en wordt intraveneus toegediend met de hulpstof hydroxypropylbetadex. Het is onbekend of hydroxypropylbetadex wordt verwijderd door peritoneaal dialyse
Hemo dialysis: Aanpassen van de dosis of het doseerinterval is niet nodig. Itraconazol is slecht oplosbaar en wordt intraveneus toegediend met de hulpstof hydroxypropylbetadex. Hydroxypropylbetadex wordt verwijderd door hemodialyse.
Interactions
Interaction with (ATC): | Interaction with: | Expected effect: |
---|---|---|
Interaction with (ATC): A02BC - Proton Pump Inhibitors |
Interaction with: geldt niet voor drank |
Expected effect: verlaging absorptie itraconazol |
Interaction with (ATC): A02BA - H2-Receptor Antagonists |
Interaction with: geldt niet voor drank |
Expected effect: verlaging absorptie itraconazol |
Interaction with (ATC): A03FA02 - Cisapride |
Interaction with: |
Expected effect: toename cardiotoxiciteit cisapride |
Interaction with (ATC): R06AX12 - Terfenadine |
Interaction with: |
Expected effect: toename cardiotoxiciteit terfenadrine |
Interaction with (ATC): J01FA09 - Clarithromycin |
Interaction with: |
Expected effect: verhoging plasmaconcentratie itraconazol |
Interaction with (ATC): C01AA05 - Digoxin |
Interaction with: |
Expected effect: verhoging plasmaconcentratie digoxine |
Interaction with (ATC): N03AB02 - Phenytoin |
Interaction with: |
Expected effect: sterke verlaging itraconazol plasmaconcentratie |
Interaction with (ATC): J05AG01 - Nevirapine |
Interaction with: |
Expected effect: verhoging plasmaconcentratie nevirapine en itraconazol |
Interaction with (ATC): J05AE - Protease Inhibitors |
Interaction with: |
Expected effect: verhoging plasmaconcentratie proteaseremmers |
Interaction with (ATC): J04AB02 - Rifampicin |
Interaction with: |
Expected effect: verlaging plasmaconcentratie itraconazol |
Interaction with (ATC): J04AB04 - Rifabutin |
Interaction with: |
Expected effect: verlaging plasmaconcentratie itraconazol |
Interaction with (ATC): L04AD01 - Ciclosporin |
Interaction with: |
Expected effect: verhoging ciclosporineconcentratie in volbloed |
Interaction with (ATC): L04AD02 - Tacrolimus |
Interaction with: |
Expected effect: verhoging plasmaconcentratie tacrolimus |
Interaction with (ATC): L04AA10 - Sirolimus |
Interaction with: |
Expected effect: verhoging plasmaconcentratie sirolimus |
Interaction with (ATC): B01AA - Vitamin K Antagonists |
Interaction with: |
Expected effect: toename werking orale anticoagulantia |
Pregnancy
Due to the expiration of the alphanumeric classification for use in pregnancy and lactation, reference is made to the current, online information of the Teratology Information Service (TIS) of LAREB:
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Zwangerschap#TOC_Middelen_bij6
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Borstvoeding#TOC_Middelen_bij16
TDM Alert
Metadata
Swab vid: M-2134.2
Updated: 06/16/2019 - 20:05
Status: Published